UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Alamar Biosciences, Inc. (NASDAQ:ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX:NHLTY, NGHLF) today announced the launch of the UK Biobank vanguard study to measure blood-based biomarkers that are of particular importance for neurodegenerative disease. The UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study will be conducted in Nightingale’s laboratories using Alamar’s NULISA platform, which is purpose-built to detect low-abundance proteins at a sensitivity not previously achievable at scale, and will measure hundreds of circulating protein biomar